Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in Vitro and in Vivo

Overview

Journal J Atheroscler Thromb

Date 2019 Sep 19

PMID 31527323

Citations 2

Authors

Yongin Cho

Hyangkyu Lee

Hyun Ki Park

Eun Yeong Choe

Hye Jin Wang

Ryeong-Hyeon Kim

Youjin Kim

Eun Seok Kang

Affiliations

Soon will be listed here.

Abstract

Aim: Most statins increase the risk of new-onset diabetes. Unlike other statins, pitavastatin is reported to exert neutral effects on serum glucose level, but the precise mechanism is unknown.

Methods: Eight-week-old male C57BL/6J mice (n=26) were fed high-fat diet (HFD, 45% fat) with 0.01% placebo, rosuvastatin, or pitavastatin for 12 weeks. Cultured HepG2, C2C12, and 3T3-L1 cells and visceral adipocytes from HFD-fed mice were treated with vehicle or 10 µM statins for 24 h. The effects of pitavastatin and rosuvastatin on intracellular insulin signaling and glucose transporter 4 (GLUT4) translocation were evaluated.

Results: After 12 weeks, the fasting blood glucose level was significantly lower in pitavastatin-treated group than in rosuvastatin-treated group (115.2±7.0 versus 137.4±22.3 mg/dL, p=0.024). Insulin tolerance significantly improved in pitavastatin-treated group as compared with rosuvastatin-treated group, and no significant difference was observed in glucose tolerance. Although plasma adiponectin and insulin levels were not different between the two statin treatment groups, the insulin-induced protein kinase B phosphorylation was weakly attenuated in pitavastatin-treated adipocytes than in rosuvastatin-treated adipocytes. Furthermore, minor attenuation in insulin-induced GLUT4 translocation to the plasma membrane of adipocytes was observed in pitavastatin-treated group.

Conclusion: Pitavastatin showed lower diabetogenic effects than rosuvastatin in mice that may be mediated by minor attenuations in insulin signaling in adipocytes.

Citing Articles

The Association of Statin Therapy with Liver and Pancreatic Fat Fraction in Type 2 Diabetes Mellitus.

Parlar M, Mutlu H, Dogantekin B, Musaoglu I, Albayrakoglu N, Yavuz M Diagnostics (Basel). 2025; 15(4).

PMID: 40002577 PMC: 11854770. DOI: 10.3390/diagnostics15040426.

Effect of pitavastatin on erythrocyte membrane fatty acid content in patients with chronic kidney disease: two-arm parallel randomized controlled trial.

Kim M, Kim S, Lee S, An W J Yeungnam Med Sci. 2024; 41(3):188-195.

PMID: 38715530 PMC: 11294791. DOI: 10.12701/jyms.2024.00094.

Real-World Analyses of the Safety Outcome among a General Population Treated with Statins: An Asian Population-Based Study.

Lin J, Chen P, Lin H, Tsai L, Lin S, Li Y J Atheroscler Thromb. 2021; 29(8):1213-1225.

PMID: 34497171 PMC: 9371755. DOI: 10.5551/jat.63076.

References

Lorza-Gil E, Salerno A, Wanschel A, Vettorazzi J, Ferreira M, Rentz T . Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice. Toxicology. 2016; 344-346:42-52. DOI: 10.1016/j.tox.2015.12.007. View

Vallejo-Vaz A, Seshasai S, Kurogi K, Michishita I, Nozue T, Sugiyama S . Effect of pitavastatin on glucose, HbA1c and incident diabetes: A meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015; 241(2):409-18. DOI: 10.1016/j.atherosclerosis.2015.06.001. View

Betteridge D, Carmena R . The diabetogenic action of statins - mechanisms and clinical implications. Nat Rev Endocrinol. 2015; 12(2):99-110. DOI: 10.1038/nrendo.2015.194. View

Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K . Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars. J Atheroscler Thromb. 2008; 15(6):345-50. DOI: 10.5551/jat.e581. View

Inami N, Nomura S, Shouzu A, Omoto S, Kimura Y, Takahashi N . Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2008; 36(1):1-8. DOI: 10.1159/000112633. View

Colbert J, Stone J . Statin use and the risk of incident diabetes mellitus: a review of the literature. Can J Cardiol. 2012; 28(5):581-9. DOI: 10.1016/j.cjca.2012.03.021. View

Chen S, Wasserman D, Mackintosh C, Sakamoto K . Mice with AS160/TBC1D4-Thr649Ala knockin mutation are glucose intolerant with reduced insulin sensitivity and altered GLUT4 trafficking. Cell Metab. 2011; 13(1):68-79. PMC: 3081066. DOI: 10.1016/j.cmet.2010.12.005. View

Khan A, Pessin J . Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia. 2002; 45(11):1475-83. DOI: 10.1007/s00125-002-0974-7. View

Sever P, Dahlof B, Poulter N, Wedel H, Beevers G, Caulfield M . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre.... Lancet. 2003; 361(9364):1149-58. DOI: 10.1016/S0140-6736(03)12948-0. View

10.

Viravaidya K, Shuler M . Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol Prog. 2004; 20(2):590-7. DOI: 10.1021/bp034238d. View

11.

Moutzouri E, Liberopoulos E, Mikhailidis D, Kostapanos M, Kei A, Milionis H . Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance. Int J Clin Pract. 2011; 65(11):1141-8. DOI: 10.1111/j.1742-1241.2011.02779.x. View

12.

Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H . Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care. 2006; 29(6):1357-62. DOI: 10.2337/dc05-1801. View

13.

Manning B . Insulin signaling: inositol phosphates get into the Akt. Cell. 2010; 143(6):861-3. PMC: 3693466. DOI: 10.1016/j.cell.2010.11.040. View

14.

Schachter M . Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005; 19(1):117-25. DOI: 10.1111/j.1472-8206.2004.00299.x. View

15.

Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-64. DOI: 10.1001/jama.2011.860. View

16.

Arnaboldi L, Corsini A . Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl. 2015; 16:1-27. DOI: 10.1016/S1567-5688(14)70002-9. View

17.

Sattar N, Ginsberg H, Ray K, Chapman M, Arca M, Averna M . The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl. 2014; 15(1):1-15. DOI: 10.1016/j.atherosclerosissup.2014.04.001. View

18.

Corsini A, Ceska R . Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?. Curr Med Res Opin. 2011; 27(8):1551-62. DOI: 10.1185/03007995.2011.589433. View

19.

Gonzalez E, McGraw T . Insulin-modulated Akt subcellular localization determines Akt isoform-specific signaling. Proc Natl Acad Sci U S A. 2009; 106(17):7004-9. PMC: 2678468. DOI: 10.1073/pnas.0901933106. View

20.

Ishihara Y, Ohmori K, Mizukawa M, Hasan A, Noma T, Kohno M . Beneficial direct adipotropic actions of pitavastatin in vitro and their manifestations in obese mice. Atherosclerosis. 2010; 212(1):131-8. DOI: 10.1016/j.atherosclerosis.2010.04.019. View